Oxford, UK; 15 February 2006 – Oxford Immunotec Ltd, the T cell measurement Company, has recently launched a new website www.oxfordimmunotec.com

The new website is accompanied by a range of web-based downloads which support the use of T‑SPOT™.TB, the Company’s first revolutionary product for the diagnosis of latent TB infection and TB disease. I have attached the new corporate profile factsheet and here is a brief overview of the company:

Oxford Immunotec is headquartered near Oxford, UK. The Company develops and sells clinical diagnostic products based on its patented T-SPOT™ technology, the first regulatory approved method for directly quantifying antigen-specific T cells. T-SPOT is a simple and extremely accurate method of studying a person’s cellular immune response to infection and can be applied to diagnose and monitor any major disease driven by a T cell response.

T-SPOT.TB is an in vitro T cell measurement assay used for diagnosing TB disease and latent TB infection and the first product from Oxford Immunotec using the T-SPOT technology. The product is extremely robust in that it gives a result every time and offers unrivalled and maintained sensitivity in high risk and immunocompromised patient groups. T-SPOT.TB is approved for sale in Europe and is designed to replace the 115 year old tuberculin skin test. As such it offers a substantially more accurate and effective tool for controlling the spread of TB, addressing a market of £600m.

Unlike the traditional Tuberculin Skin Test, T-SPOT.TB incorporates a positive control, allowing the user to distinguish between a genuine negative result and one which is indeterminate (ie an inconclusive result) as a result of a technical failure.

T-SPOT is a trademark of Oxford Immunotec.

If you are writing on this area or would be interested in profiling the Company or visiting them, please do let me know.